Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Emicizumab for the treatment of acquired hemophilia A.
Knoebl P, Thaler J, Jilma P, Quehenberger P, Gleixner K, Sperr WR. Knoebl P, et al. Blood. 2021 Jan 21;137(3):410-419. doi: 10.1182/blood.2020006315. Blood. 2021. PMID: 32766881 Free article.
N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia.
Graf I, Greiner G, Marculescu R, Gleixner KV, Herndlhofer S, Stefanzl G, Knoebl P, Jäger U, Hauswirth A, Schwarzinger I, Thalhammer R, Kundi M, Hoermann G, Mitterbauer-Hohendanner G, Valent P, Sperr WR. Graf I, et al. Among authors: gleixner kv. Am J Hematol. 2023 Feb;98(2):290-299. doi: 10.1002/ajh.26805. Epub 2023 Jan 1. Am J Hematol. 2023. PMID: 36588398 Free PMC article.
Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis.
Toledo MAS, Gatz M, Sontag S, Gleixner KV, Eisenwort G, Feldberg K, Hamouda AEI, Kluge F, Guareschi R, Rossetti G, Sechi AS, Dufva OMJ, Mustjoki SM, Maurer A, Schüler HM, Goetzke R, Braunschweig T, Kaiser A, Panse J, Jawhar M, Reiter A, Hilberg F, Ettmayer P, Wagner W, Koschmieder S, Brümmendorf TH, Valent P, Chatain N, Zenke M. Toledo MAS, et al. Among authors: gleixner kv. Blood. 2021 Apr 15;137(15):2070-2084. doi: 10.1182/blood.2019004509. Blood. 2021. PMID: 33512435 Free article.
Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.
Sperr WR, Herndlhofer S, Gleixner K, Girschikofsky M, Weltermann A, Machherndl-Spandl S, Sliwa T, Poehnl R, Buxhofer-Ausch V, Strecker K, Hoermann G, Knoebl P, Jaeger U, Geissler K, Kundi M, Valent P. Sperr WR, et al. Am J Hematol. 2017 Oct;92(10):E567-E574. doi: 10.1002/ajh.24847. Epub 2017 Aug 17. Am J Hematol. 2017. PMID: 28699225 Free PMC article. Clinical Trial.
Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
Gleixner KV, Rebuzzi L, Mayerhofer M, Gruze A, Hadzijusufovic E, Sonneck K, Vales A, Kneidinger M, Samorapoompichit P, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Sillaber C, Willmann M, Valent P. Gleixner KV, et al. Exp Hematol. 2007 Oct;35(10):1510-21. doi: 10.1016/j.exphem.2007.06.005. Epub 2007 Aug 2. Exp Hematol. 2007. PMID: 17681669 Free article.
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C, Lee FY, Aichberger KJ, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P. Gleixner KV, et al. Haematologica. 2007 Nov;92(11):1451-9. doi: 10.3324/haematol.11339. Haematologica. 2007. PMID: 18024392 Free article.
71 results